Medtronic PLC $MDT Shares Acquired by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC grew its holdings in Medtronic PLC (NYSE:MDT) by 15.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 15,646 shares of the medical technology company’s stock after buying an additional 2,049 shares during the period. Colton Groome Financial Advisors LLC’s holdings in Medtronic were worth $1,364,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Register Financial Advisors LLC lifted its position in Medtronic by 15.7% in the second quarter. Register Financial Advisors LLC now owns 4,873 shares of the medical technology company’s stock valued at $425,000 after buying an additional 662 shares during the last quarter. Dakota Wealth Management raised its stake in shares of Medtronic by 4.9% in the 2nd quarter. Dakota Wealth Management now owns 74,819 shares of the medical technology company’s stock valued at $6,522,000 after acquiring an additional 3,514 shares during the period. Perigon Wealth Management LLC lifted its holdings in shares of Medtronic by 8.0% in the 2nd quarter. Perigon Wealth Management LLC now owns 14,831 shares of the medical technology company’s stock worth $1,293,000 after acquiring an additional 1,096 shares during the last quarter. Pitti Group Wealth Management LLC boosted its position in shares of Medtronic by 1.6% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 9,063 shares of the medical technology company’s stock worth $790,000 after purchasing an additional 142 shares during the period. Finally, TD Private Client Wealth LLC increased its holdings in Medtronic by 19.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 117,926 shares of the medical technology company’s stock valued at $10,280,000 after purchasing an additional 19,501 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Down 1.5%

Medtronic stock opened at $94.26 on Friday. The company has a market capitalization of $120.91 billion, a P/E ratio of 25.97, a PEG ratio of 2.52 and a beta of 0.77. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $96.25. The stock has a 50-day simple moving average of $92.48 and a 200-day simple moving average of $88.39.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Analysts Set New Price Targets

Several research firms have recently commented on MDT. Argus raised their price target on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Wolfe Research upgraded Medtronic from an “underperform” rating to a “peer perform” rating in a report on Monday, June 30th. BTIG Research reiterated a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. Robert W. Baird raised their price objective on shares of Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, August 20th. Finally, Daiwa Capital Markets lifted their price objective on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.27.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction dated Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.26% of the stock is currently owned by insiders.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.